Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma

Loes H. C. Nissen*, Marieke Pierik, Lauranne A. A. P. Derikx, Elke de Jong, Wietske Kievit, Tim R. A. van den Heuvel, Alexander R. van Rosendael, Elsemieke I. Plasmeijer, Pieter Dewint, Rob H. A. Verhoeven, Lucy I. H. Overbeek, Iris D. Nagtegaal, Frank Hoentjen, Andrea E. van der Meulen-de Jong, Dutch Initiative Crohn and Colitis, PALGA Grp, IBD & Melanoma Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2018-2026
Number of pages9
JournalInflammatory Bowel Diseases
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 2017

Keywords

  • inflammatory bowel diseases
  • melanoma
  • immunosuppressive therapy
  • INFLAMMATORY-BOWEL-DISEASE
  • NONMELANOMA SKIN CANCERS
  • EVIDENCE-BASED CONSENSUS
  • TRANSPLANT RECIPIENTS
  • ULCERATIVE-COLITIS
  • METAANALYSIS
  • SURVIVAL
  • IMMUNOSUPPRESSION
  • EPIDEMIOLOGY
  • MALIGNANCIES

Cite this

Nissen, L. H. C., Pierik, M., Derikx, L. A. A. P., de Jong, E., Kievit, W., van den Heuvel, T. R. A., van Rosendael, A. R., Plasmeijer, E. I., Dewint, P., Verhoeven, R. H. A., Overbeek, L. I. H., Nagtegaal, I. D., Hoentjen, F., van der Meulen-de Jong, A. E., Dutch Initiative Crohn and Colitis, PALGA Grp, & IBD & Melanoma Grp (2017). Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. Inflammatory Bowel Diseases, 23(11), 2018-2026. https://doi.org/10.1097/MIB.0000000000001191